Crinetics Pharmaceuticals (CRNX) Assets Average (2018 - 2026)

Crinetics Pharmaceuticals' Assets Average history runs 9 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Assets Average fell 9.6% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (down 9.6% YoY), while the FY2025 annual figure was $1.3 billion, up 23.72% from the prior year.
• Assets Average for Q1 2026 stood at $1.3 billion, up from $1.2 billion in the prior quarter.
• The five-year high for Assets Average was $1.4 billion in Q1 2025, with the low at $303.6 million in Q2 2023.
• The 5-year median for Assets Average is $806.8 million (2024), against an average of $794.8 million.
• The sharpest annual moves came in 2023 and 2024: Assets Average slipped 19.57% in 2023, then soared 215.13% in 2024.
• Crinetics Pharmaceuticals' Assets Average stood at $368.5 million in 2022, then surged by 73.24% to $638.4 million in 2023, then surged by 85.76% to $1.2 billion in 2024, then retreated by 2.09% to $1.2 billion in 2025, then increased by 8.84% to $1.3 billion in 2026.
• Business Quant data shows CRNX's Assets Average at $1.3 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.2 billion in Q3 2025.